Related to Study Finds PD Patients and Relatives Have Increased Risk of Melanoma and Prostate Cancer

• Melanoma Appears to Not Follow the Cancer Stem Cell Model
  
• The Link between Proton-Pump Inhibitors and Birth Defects
  
• Researchers Uncover Drug-Resistance Mechanisms in BRAF Melanoma
  
• Amsterdam Molecular Therapeutics Gains Additional Rights to Amgen GDNF Gene
  
• Myriad Takes Over Testing Platform from Melanoma Diagnostics
  
• Safety Concerns Lead Lilly to Suspend Phase III Melanoma Trial
  
• MJFF Awards AFFiRiS $475K to Complete Preclinical Development of PD Vaccine
  
• GSK Pays Impax $11.5M Up Front for Non-U.S. Rights to Late-Stage PD Therapy
  
• Provectus Receives $1M Investment from LPC
  
• Civitas Raises $20M for Parkinson Disease Program
  
• Merck Serono Partners with Domain to Develop mGluR4 PAM Candidates for PD
  
• Tolmar Grants Astellas European Rights to Prostate Cancer Therapy in New Territories
  
• miR-34a Found to Suppress Prostate Cancer Stem Cells
  
• Phase III Study Shows Mutation-Specific Metastatic Melanoma Drug Boosts Survival
  
• The Research Foundation of SUNY to Help Sunshine Biopharma Push Anticancer Agent into the Clinic
  
• Amgen to Buy BioVex for $425M in Cash for Phase III-Stage Oncolytic Vaccine
  
• U.S.-Euro Research Consortium Established to Map Genetic Basis of AD
  
• Daiichi Sankyo to Buy Plexxikon for $805M Following Positive Phase III Melanoma Trial Data
  
• GTx and Ipsen End Prostate Cancer Collaboration due to Costs of FDA-Requested Phase III Study
  
• GSK Nixes Neuroscience Collaboration with Targacept